News | August 16, 2022
NGL Fine-Chem planning greenfield expansion at Tarapur
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Company appoints five new independent directors to reconstituted board
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The WAVEsystem with the WAVEcontrol 4.0 embedded
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
